3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Classical hematology
1
Conditions
Thrombocytopenia
4
Leukemia, Myeloid, Acute
4
Leukemia
3
Sarcoma
1
Recurrence
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Connective and Soft Tissue
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Erythroblastic, Acute
1
Leukemia, Eosinophilic, Acute
1
Leukemia, Basophilic, Acute
1
Jacobs syndrome
1
Congenital Abnormalities
1
Bone Neoplasms
1
Interventions
Rituximab
24
Cyclophosphamide
20
fludarabine phosphate
16
Mycophenolic Acid
13
Filgrastim
12
Cyclosporine
12
Bortezomib
12
Antilymphocyte Serum
11
Whole-Body Irradiation
10
Peripheral Blood Stem Cell Transplantation
10
Tacrolimus
9
Lenalidomide
9
fludarabine
8
Radiotherapy
7
Methotrexate
7
Cord Blood Stem Cell Transplantation
7
Melphalan
6
Busulfan
6
venetoclax
5
Etoposide
5
tanespimycin
4
ibrutinib
4
Polymerase Chain Reaction
4
Methylprednisolone
4
Granulocyte Colony-Stimulating Factor
4
Flow Cytometry
4
ublituximab
3
thymoglobulin
3
sargramostim
3
carfilzomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, Mantle-Cell
×
eltrombopag
×
Clear all
NCT01500538
2016-02-15
VEIL
Peter MacCallum Cancer Centre, Australia
Phase 2
Terminated
1 enrolled